Bioventix Plc (LON:BVXP) target price raised to 1,450.00GBX, reported today by finnCap
- Updated: October 16, 2016
Bioventix Plc (LON:BVXP) had its target price raised to 1,450.00GBX by finnCap in a report released Monday October 17, 2016. The new target price indicates a possible downside of -0.06% based on the company's last stock close price.
Previously on 8/30/2016, finnCap reported about Bioventix Plc (LON:BVXP) held steady the target price at 1,350.00GBX. At the time, this indicated a possible upside of 0%.
Yesterday Bioventix Plc (LON:BVXP) traded 8.28% higher at 1,550.00GBX. The company’s 50-day moving average is 1,158.61GBX and its 200-day moving average is 1,044.63GBX. The last stock close price is up 50.29% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 10,759 shares of the stock were exchanged, down from an average trading volume of 13,829
See Chart Below
Bioventix Plc has a 52 week low of 899.50GBX and a 52 week high of 1,600.00GBX with a P/E ratio of 27.94 The company’s market cap is currently 0 GBX.
About Bioventix Plc (LON:BVXP)
Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company uses its technology in the fields of clinical diagnostics. Its develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse and other diseases. Its product, Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biologic effects.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.